NCT02009397

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: University of Louisville · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body. This study will also demostrate how safe the combined drugs are when used to treat patients with Stage 3 or Stage 4 melanoma (metastatic melanoma), which cannot be removed by surgery.

Conditions

• Metastatic Melanoma

Interventions

Type	Name	Description
DRUG	Ipilimumab
DRUG	GM-CSF

Timeline

• Start date: 2012-02-01
• Primary completion: 2016-11-01
• Completion: 2016-11-01
• First posted: 2013-12-12
• Last updated: 2021-11-22
• Results posted: 2021-11-22

Locations

1 site across 1 country: United States